(S (NP (NP (DT The) (JJ high) (NN risk) (NN population)) (PP (IN of) (NP (NP (JJ cardiovascular) (NN disease)) (PRN (-LRB- -LRB-) (NP (NNP CVD)) (-RRB- -RRB-))))) (VP (VBZ is) (ADVP (RB simultaneously)) (PP (IN at) (NP (NP (JJ high) (NN risk)) (PP (IN of) (NP (NN lung) (NN cancer)))))) (. .))
(S (PP (VBN Given) (NP (NP (DT the) (NN dominance)) (PP (IN of) (NP (NP (JJ low) (NN dose) (VBN computed) (NN tomography)) (PRN (-LRB- -LRB-) (NP (NNP LDCT)) (-RRB- -RRB-)))) (PP (IN for) (NP (NN lung) (NN cancer) (NN screening))))) (, ,) (NP (NP (DT the) (NN feasibility)) (PP (IN of) (S (VP (VBG extracting) (NP (NP (NN information)) (PP (IN on) (NP (NNP CVD)))) (PP (IN from) (NP (DT the) (JJ same) (NNP LDCT) (NN scan))))))) (VP (MD would) (VP (VB add) (NP (JJ major) (NN value)) (PP (TO to) (NP (NNS patients))) (PP (IN at) (NP (DT no) (JJ additional) (NN radiation) (NN dose))))) (. .))
(S (ADVP (RB However)) (, ,) (PP (PP (IN with) (NP (NP (JJ strong) (NN noise)) (PP (IN in) (NP (NNP LDCT) (NNS images))))) (CC and) (PP (IN without) (NP (NN electrocardiogram) (PRN (-LRB- -LRB-) (NNP ECG) (-RRB- -RRB-)) (NN gating)))) (, ,) (NP (NP (NNP CVD) (NN risk) (NN analysis)) (PP (IN from) (NP (NNP LDCT)))) (VP (VBZ is) (ADJP (RB highly) (JJ challenging))) (. .))
(S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP present) (NP (NP (DT an) (JJ innovative) (NN deep) (VBG learning) (NN model)) (SBAR (S (VP (TO to) (VP (VB address) (NP (DT this) (NN challenge)))))))) (. .))
(S (NP (PRP$ Our) (JJ deep) (NN model)) (VP (VP (VBD was) (VP (VP (VBN trained) (PP (IN with) (NP (CD 30,286) (NNP LDCT) (NNS volumes)))) (CC and) (VP (VBD achieved) (NP (NP (DT the) (JJ state-of-the-art) (NN performance)) (PRN (-LRB- -LRB-) (NP (NP (NN area)) (PP (IN under) (NP (DT the) (NN curve))) (PRN (-LRB- -LRB-) (NP (NNP AUC)) (-RRB- -RRB-)) (PP (IN of) (NP (CD 0.869)))) (-RRB- -RRB-))) (PP (IN on) (NP (CD 2,085) (NNP National) (NNP Lung) (NNP Cancer) (NNP Screening) (NNP Trial) (PRN (-LRB- -LRB-) (NNP NLST) (-RRB- -RRB-)) (VBZ subjects)))))) (, ,) (CC and) (VP (ADVP (RB effectively)) (VBN identified) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ high) (NNP CVD) (NN mortality) (NNS risks)) (PRN (-LRB- -LRB-) (NP (NP (NNP AUC)) (PP (IN of) (NP (CD 0.768)))) (-RRB- -RRB-))))))) (. .))
(S (NP (PRP$ Our) (JJ deep) (NN model)) (VP (VBD was) (ADVP (RB further)) (VP (VBN calibrated) (PP (IN against) (NP (NP (DT the) (JJ clinical) (NN gold) (NN standard) (NNP CVD) (NN risk) (NNS scores)) (PP (IN from) (NP (NNP ECG-gated) (JJ dedicated) (NN cardiac) (NNP CT))) (, ,) (PP (VBG including) (NP (NP (JJ coronary) (NN artery) (NN calcification) (PRN (-LRB- -LRB-) (NNP CAC) (-RRB- -RRB-)) (NN score)) (, ,) (NP (NNP CAD-RADS) (NN score)) (CC and) (NP (NP (NNP MESA) (JJ 10-year) (NNP CHD) (NN risk) (NN score)) (PP (IN from) (NP (NP (DT an) (JJ independent) (NN dataset)) (PP (IN of) (NP (CD 106) (NNS subjects)))))))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN validation) (NN study))) (, ,) (NP (PRP$ our) (NN model)) (VP (VBD achieved) (NP (NP (NNP AUC)) (PP (IN of) (NP (CD 0.942) (, ,) (CD 0.809) (CC and) (CD 0.817))) (PP (IN for) (NP (NP (NNP CAC) (, ,) (NNP CAD-RADS) (CC and) (NNP MESA) (NNS scores)) (, ,) (ADVP (RB respectively)))))) (. .))
(S (NP (PRP$ Our) (JJ deep) (NN learning) (NN model)) (VP (VBZ has) (NP (DT the) (JJ potential) (S (VP (TO to) (VP (VB convert) (NP (NP (NNP LDCT)) (PP (IN for) (NP (NN lung) (NN cancer) (VBG screening)))) (PP (IN into) (NP (NP (JJ dual-screening) (JJ quantitative) (NN tool)) (PP (IN for) (NP (NNP CVD) (NN risk) (NN estimation)))))))))) (. .))
